Breaking through the oxygen ceiling: Evidence-based strategies for conquering refractory hypoxemia

Primary endpoint selectionThis review primarily focuses on mortality as the most clinically meaningful endpoint when evaluating interventions for refractory hypoxemia.While physiological parameters (oxygenation indices, compliance) and process measures (ventilator-free days) provide valuable information about mechanism and potential benefit, mortality remains the gold standard for determining the true clinical impact of novel interventions.For each trial discussed, we highlight whether a statistically significant mortality benefit was demonstrated, allowing clinicians to better understand which interventions have definitively improved survival.Table 1 provides a comprehensive summary of all interventions reviewed, their effect on mortality, and the quality of supporting evidence. EVOLVING LANDSCAPE OF LUNG-PROTECTIVE VENTILATION STRATEGIES Ultra-protective ventilation with extracorporeal supportThe concept of "ultra-protective ventilation" has gained prominence with the integration of extracorporeal membrane oxygenation (ECMO) or extracorporeal carbon dioxide removal (ECCO 2 R) systems.The EOLIA trial (ECMO to Rescue Lung Injury in Severe ARDS), published by Combes et al. [1] in 2018, represented a pivotal study that, while not meeting its primary endpoint of mortality reduction at 60 days, demonstrated important benefits when analyzed with alternative statistical approaches.The primary analysis showed a mortality of 35% in the ECMO group versus 46% in the conventional management group (P = 0.09), which narrowly missed statistical significance. Key clinical takeaway:ECMO should be considered early in severe ARDS patients with a P/F ratio <80 mmHg for >6 h or <50 mmHg for >3 h despite optimal conventional management.Centers should establish protocols for early identification of potential ECMO candidates and develop referral networks with ECMO-capable centers when this capability is not available locally.The high crossover rate (28%) in the EOLIA trial suggests that rescue ECMO for rapidly deteriorating patients may be beneficial.A post-hoc Bayesian analysis of the EOLIA trial data by Goligher et al. (2018) [11] demonstrated a high probability (>95%) of mortality benefit with early ECMO implementation.Their analysis suggested that for every 6 patients treated with ECMO, one additional life could